METTL25: A Protein Regulating Microtubules and Disease Development

Target Name: METTL25

NCBI ID: G84190

METTL25

METTL25: A Protein Regulating Microtubules and Disease Development

METTL25, also known as METTL25 variant 1, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of microtubules, which are essential for cell division and transport of organelles within cells. METTL25 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a result, METTL25 has become a focus of interest for researchers as a potential drug target or biomarker.

The METTL25 protein is composed of 21 kDa伪 and 21 kDa尾 subunits that are held together by a disulfide bond. The 伪 subunit consists of a catalytic center, a 155 amino acid long carboxy-terminal region, and a 14 amino acid long N-terminal region. The 尾 subunit is similar to the 伪 subunit but has a different N-terminus.

METTL25 is a microtubule-associated protein that plays a critical role in the regulation of microtubule dynamics and stability. It is expressed in a variety of tissues, including the brain, heart, and kidneys, and has been shown to be involved in the development and progression of various diseases.

One of the most significant functions of METTL25 is its role in the regulation of microtubule stability. Microtubules are dynamic structures that play a central role in the regulation of cell division, transport of organelles, and intracellular signaling. METTL25 is involved in the regulation of microtubule stability by interacting with the microtubule protein TP100. This interaction between METTL25 and TP100 allows METTL25 to influence the stability of microtubules and affect the dynamics of cellular processes.

In addition to its role in microtubule regulation, METTL25 has also been shown to be involved in the development and progression of various diseases. For example, METTL25 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. METTL25 has also been shown to be involved in the development of cancer, as it has been shown to promote the growth and survival of cancer cells.

METTL25 has also been shown to be involved in the regulation of cellular signaling pathways. For example, METTL25 has been shown to be involved in the regulation of theNotch signaling pathway, a pathway that plays a role in the development and regulation of various diseases, including cancer. METTL25 has also been shown to be involved in the regulation of the TGF-β signaling pathway, a pathway that is involved in the development and regulation of various diseases, including cancer.

In conclusion, METTL25 is a protein that is involved in the regulation of microtubule dynamics and stability, as well as the development and progression of various diseases. As a result, METTL25 has become a focus of interest for researchers as a potential drug target or biomarker. Further research is needed to fully understand the role of METTL25 in cellular processes and its potential as a drug target or biomarker.

Protein Name: Methyltransferase Like 25

Functions: Probable methyltransferase

The "METTL25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about METTL25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets